Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
2.
Br J Dermatol ; 177(4): 1102-1112, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28346659

ABSTRACT

BACKGROUND: A strong association has been documented between HLA-B*15:02 and carbamazepine-induced severe cutaneous adverse reactions (SCARs) in Asians. Human leucocyte antigen testing is potentially valuable in many countries to facilitate early recognition of patient susceptibility to SCARs. OBJECTIVES: To determine the cost-effectiveness of universal HLA-B*15:02 screening in preventing carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in an ethnically diverse Malaysian population. METHODS: A hybrid model of a decision tree and Markov model was developed to evaluate three strategies for treating newly diagnosed epilepsy among adults: (i) carbamazepine initiation without HLA-B*15:02 screening (current practice); (ii) universal HLA-B*15:02 screening prior to carbamazepine initiation; and (iii) alternative treatment [sodium valproate (VPA)] prescribing without HLA-B*15:02 screening. Base-case analysis and sensitivity analyses were performed over a lifetime time horizon. Incremental cost-effectiveness ratios were calculated. RESULTS: Both universal HLA-B*15:02 screening and VPA prescribing were dominated by current practice. Compared with current practice, universal HLA-B*15:02 screening resulted in a loss of 0·0255 quality-adjusted life years (QALYs) at an additional cost of 707 U.S. dollars (USD); VPA prescribing resulted in a loss of 0·2622 QALYs at an additional cost of USD 4127, owing to estimated differences in antiepileptic treatment efficacy. CONCLUSIONS: Universal HLA-B*15:02 screening is unlikely to be a cost-effective intervention in Malaysia. However, with the emergence of an ethnically diverse population in many other countries, this may render HLA-B*15:02 screening a viable intervention when an increasing proportion of the population is at risk and an equally effective yet safer antiepileptic drug is available.


Subject(s)
Anticonvulsants/adverse effects , Carbamazepine/adverse effects , HLA-B15 Antigen/metabolism , Stevens-Johnson Syndrome/prevention & control , Adolescent , Adult , Asian People/ethnology , Cost-Benefit Analysis , Efficiency , Epilepsy/drug therapy , Epilepsy/ethnology , Humans , Malaysia/ethnology , Markov Chains , Mass Screening/economics , Middle Aged , Quality-Adjusted Life Years , Stevens-Johnson Syndrome/economics , Stevens-Johnson Syndrome/ethnology , Young Adult
3.
Clin Pharmacol Ther ; 102(3): 397-404, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28198005

ABSTRACT

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.


Subject(s)
Anticoagulants/administration & dosage , Cytochrome P-450 CYP2C9/genetics , Cytochrome P450 Family 4/genetics , Vitamin K Epoxide Reductases/genetics , Warfarin/administration & dosage , Adult , Child , Dose-Response Relationship, Drug , Genotype , Humans , Pharmacogenetics , Practice Guidelines as Topic
4.
Clin Pharmacol Ther ; 102(3): 502-510, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28090649

ABSTRACT

Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of pharmacogenetics. The Translational Pharmacogenetics Program (TPP) of the National Institutes of Health (NIH) Pharmacogenomics Research Network was established in 2011 to catalog and contribute to the development of pharmacogenetic implementations at eight US healthcare systems, with the goal to disseminate real-world solutions for the barriers to clinical pharmacogenetic implementation. The TPP collected and normalized pharmacogenetic implementation metrics through June 2015, including gene-drug pairs implemented, interpretations of alleles and diplotypes, numbers of tests performed and actionable results, and workflow diagrams. TPP participant institutions developed diverse solutions to overcome many barriers, but the use of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the institutions. The TPP also collected some pharmacogenetic implementation outcomes (scientific, educational, financial, and informatics), which may inform healthcare systems seeking to implement their own pharmacogenetic testing programs.


Subject(s)
Delivery of Health Care/organization & administration , Pharmacogenetics/methods , Practice Guidelines as Topic , Translational Research, Biomedical/organization & administration , Alleles , Humans , National Institutes of Health (U.S.) , United States
5.
J Thromb Haemost ; 15(4): 735-743, 2017 04.
Article in English | MEDLINE | ID: mdl-28135054

ABSTRACT

Essentials Genetic variants controlling gene regulation have not been explored in pharmacogenomics. We tested liver expression quantitative trait loci for association with warfarin dose response. A novel predictor for increased warfarin dose response in African Americans was identified. Precision medicine must take into account population-specific variation in gene regulation. SUMMARY: Background Warfarin is commonly used to control and prevent thromboembolic disorders. However, because of warfarin's complex dose-requirement relationship, safe and effective use is challenging. Pharmacogenomics-guided warfarin dosing algorithms that include the well-established VKORC1 and CYP2C9 polymorphisms explain only a small proportion of inter-individual variability in African Americans (AAs). Objectives We aimed to assess whether transcriptomic analyses could be used to identify regulatory variants associated with warfarin dose response in AAs. Patients/Methods We identified a total of 56 expression quantitative trait loci (eQTLs) for CYP2C9, VKORC1 and CALU derived from human livers and evaluated their association with warfarin dose response in two independent AA warfarin patient cohorts. Results We found that rs4889606, a strong cis-eQTL for VKORC1 (log10 Bayes Factor = 12.02), is significantly associated with increased warfarin daily dose requirement (ß = 1.1; 95% confidence interval [CI] 0.46 to 1.8) in the discovery cohort (n = 305) and in the replication cohort (ß = 1.04; 95% CI 0.33 -1.7; n = 141) after conditioning on relevant covariates and the VKORC1 -1639G>A (rs9923231) variant. Inclusion of rs4889606 genotypes, along with CYP2C9 alleles, rs9923231 genotypes and clinical variables, explained 31% of the inter-patient variability in warfarin dose requirement. We demonstrate different linkage disequilibrium patterns in the region encompassing rs4889606 and rs9923231 between AAs and European Americans, which may explain the increased dose requirement found in AAs. Conclusion Our approach of interrogating eQTLs identified in liver has revealed a novel predictor of warfarin dose response in AAs. Our work highlights the utility of leveraging information from regulatory variants mapped in the liver to uncover novel variants associated with drug response and the importance of population-specific research.


Subject(s)
Genetic Variation , Thromboembolism/ethnology , Thromboembolism/genetics , Warfarin/administration & dosage , Adult , Black or African American , Aged , Algorithms , Calcium-Binding Proteins/genetics , Cohort Studies , Cytochrome P-450 CYP2C9/genetics , Female , Gene Expression Profiling , Gene Expression Regulation , Genotype , Humans , Linkage Disequilibrium , Liver/drug effects , Liver/metabolism , Male , Middle Aged , Pharmacogenetics , Precision Medicine , Quantitative Trait Loci , Thromboembolism/drug therapy , Vitamin K Epoxide Reductases/genetics
6.
Pharmacogenomics J ; 17(6): 494-500, 2017 12.
Article in English | MEDLINE | ID: mdl-27503578

ABSTRACT

Using population pharmacokinetic analysis (PPK), we attempted to identify predictors of S-warfarin clearance (CL(S)) and to clarify population differences in S-warfarin pharmacokinetics among a cohort of 378 African American, Asian and white patients. Significant predictors of CL(S) included clinical (age, body weight and sex) and genotypic (CYP2C9*2,*3 and *8) factors, as well as African American ethnicity, the median CL(S) being 30% lower in the latter than in Asians and whites (170 versus 243 and 250 ml h-1, P<0.01). The plasma S-warfarin (Cp(S)) time courses following the genotype-based dosing algorithms simulated using the PPK estimates showed African Americans with CYP2C9*1/*1 and any of the VKORC1 genotypes would have an average Cp(S) at steady state 1.5-1.8 times higher than in Asians and whites. These results indicate warfarin dosing algorithms should be evaluated in each respective ethnic population. Further study of a large African American cohort will be necessary to confirm the present findings.


Subject(s)
Anticoagulants , Asian People/genetics , Black or African American/genetics , Cytochrome P-450 CYP2C9/genetics , Vitamin K Epoxide Reductases/genetics , Warfarin , White People/genetics , Algorithms , Anticoagulants/administration & dosage , Anticoagulants/blood , Cohort Studies , Dose-Response Relationship, Drug , Female , Genotype , Humans , Male , Metabolic Clearance Rate/genetics , Middle Aged , Models, Biological , Pharmacogenomic Testing , Pharmacogenomic Variants , Polymorphism, Single Nucleotide , Warfarin/administration & dosage , Warfarin/blood
7.
Clin Pharmacol Ther ; 101(5): 675-683, 2017 May.
Article in English | MEDLINE | ID: mdl-28032893

ABSTRACT

Achieving therapeutic anticoagulation efficiently with warfarin is important to reduce thrombotic and bleeding risks and is influenced by genotype. Utilizing data from a diverse population of 257 patients who received VKORC1 and CYP2C9 genotype-guided warfarin dosing, we aimed to examine genotype-associated differences in anticoagulation endpoints and derive a novel pharmacogenetic nomogram to more optimally dose warfarin. We observed significant differences across patients with 0, 1, or ≥2 reduced-function VKORC1 or CYP2C9 alleles, respectively, in time to achieve therapeutic international normalized ratio (INR) (7.8 ± 5.8, 7.2 ± 4.7, and 5.4 ± 4.6 days, P = 0.0004) and mean percentage of time in therapeutic range in the first 28 days (22.2, 27.8, and 32.2%, P = 0.0127) with use of existing pharmacogenetic algorithms. These data suggest that more aggressive dosing is necessary for patients with 0 to 1 VKORC1/CYP2C9 variants to more efficiently achieve therapeutic anticoagulation. Herein, we provide a novel kinetic/pharmacodynamic-derived dosing nomogram optimized for a heterogeneous patient population.


Subject(s)
Anticoagulants/administration & dosage , Pharmacogenetics , Warfarin/administration & dosage , Algorithms , Alleles , Anticoagulants/pharmacokinetics , Anticoagulants/therapeutic use , Cytochrome P-450 CYP2C9/genetics , Dose-Response Relationship, Drug , Endpoint Determination , Female , Genotype , Humans , Male , Middle Aged , Vitamin K Epoxide Reductases/genetics , Warfarin/pharmacokinetics , Warfarin/therapeutic use
9.
Clin Transl Sci ; 9(1): 36-42, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26751406

ABSTRACT

Genotype-based algorithms that include VKORC1 and CYP2C9 genotypes are less predictive of warfarin dose variability in Africans as opposed to Europeans. Polymorphisms in GGCX, FPGS, or STX1B are associated with warfarin dose requirements in African-Americans. We sought to determine if they influenced warfarin dose in European-Americans, and another African population, specifically Egyptians. We genotyped 529 adults (n = 325 European-Americans, 204 Egyptians) on a stable warfarin dose for GGCX rs12714145 and rs10654848, FPGS rs7856096, and STX1B rs4889606. Rs12714145, rs10654848, and rs7856096 were not associated with warfarin dose, whereas STX1B rs4889606 was a significant determinant in univariate analysis (P < 0.0001) in both cohorts. However, STX1B rs4889606 was in high linkage disequilibrium with VKORC1-1639 G>A, and was no longer significant after including VKORC1-1639 G>A in the regression model. Based on these data, the polymorphisms do not appear to influence, in a clinically important way, warfarin dose requirements in European-Americans and Egyptians.


Subject(s)
Carbon-Carbon Ligases/genetics , Peptide Synthases/genetics , Polymorphism, Single Nucleotide/genetics , Syntaxin 1/genetics , Warfarin/administration & dosage , White People/genetics , Adult , Aged , Cohort Studies , Dose-Response Relationship, Drug , Egypt , Female , Humans , Linkage Disequilibrium/genetics , Male , Microsatellite Repeats/genetics , Middle Aged , Regression Analysis , Warfarin/pharmacology
10.
Clin Pharmacol Ther ; 96(1): 22-4, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24942399

ABSTRACT

Genotype is well recognized to influence the dose of warfarin necessary for therapeutic anticoagulation. Recent randomized controlled trials evaluating the clinical utility of genotype-guided warfarin dosing have produced varying results. We review the design and results of the recent clinical trials, assess the impact of their findings on warfarin dosing, and examine unanswered questions related to clinical implementation of warfarin pharmacogenetics.


Subject(s)
Anticoagulants/administration & dosage , Warfarin/administration & dosage , Anticoagulants/pharmacokinetics , Aryl Hydrocarbon Hydroxylases/genetics , Clinical Trials as Topic , Cytochrome P-450 CYP2C9 , Genotype , Humans , Pharmacogenetics , Racial Groups , Vitamin K Epoxide Reductases/genetics , Warfarin/pharmacokinetics
12.
Pharmacogenomics J ; 14(3): 223-8, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24018621

ABSTRACT

Using a derivation cohort (N=349), we developed the first warfarin dosing algorithm that includes recently discovered polymorphisms in VKORC1 and CYP2C9 associated with warfarin dose requirement in African Americans (AAs). We tested our novel algorithm in an independent cohort of 129 AAs and compared the dose prediction to the International Warfarin Pharmacogenetics Consortium (IWPC) dosing algorithms. Our algorithm explains more of the phenotypic variation (R(2)=0.27) than the IWPC pharmacogenomics (R(2)=0.15) or clinical (R(2)=0.16) algorithms. Among high-dose patients, our algorithm predicted a higher proportion of patients within 20% of stable warfarin dose (45% vs 29% and 2% in the IWPC pharmacogenomics and clinical algorithms, respectively). In contrast to our novel algorithm, a significant inverse correlation between predicted dose and percent West African ancestry was observed for the IWPC pharmacogenomics algorithm among patients requiring ⩾60 mg per week (ß=-2.04, P=0.02).


Subject(s)
Anticoagulants/therapeutic use , Pharmacogenetics , Warfarin/therapeutic use , Anticoagulants/pharmacokinetics , Cohort Studies , Cytochrome P-450 CYP2C9/genetics , Female , Humans , Male , Vitamin K Epoxide Reductases/genetics , Warfarin/pharmacokinetics
13.
Clin Pharmacol Ther ; 92(6): 746-56, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23132553

ABSTRACT

A systematic review and a meta-analysis were performed to quantify the accumulated information from genetic association studies investigating the impact of the CYP4F2 rs2108622 (p.V433M) polymorphism on coumarin dose requirement. An additional aim was to explore the contribution of the CYP4F2 variant in comparison with, as well as after stratification for, the VKORC1 and CYP2C9 variants. Thirty studies involving 9,470 participants met prespecified inclusion criteria. As compared with CC-homozygotes, T-allele carriers required an 8.3% (95% confidence interval (CI): 5.6-11.1%; P < 0.0001) higher mean daily coumarin dose than CC homozygotes to reach a stable international normalized ratio (INR). There was no evidence of publication bias. Heterogeneity among studies was present (I(2) = 43%). Our results show that the CYP4F2 p.V433M polymorphism is associated with interindividual variability in response to coumarin drugs, but with a low effect size that is confirmed to be lower than those contributed by VKORC1 and CYP2C9 polymorphisms.


Subject(s)
Coumarins/administration & dosage , Cytochrome P-450 Enzyme System/genetics , Polymorphism, Genetic/genetics , Aged , Aged, 80 and over , Algorithms , Alleles , Aryl Hydrocarbon Hydroxylases/genetics , Cohort Studies , Coumarins/therapeutic use , Cross-Sectional Studies , Cytochrome P-450 CYP2C9 , Cytochrome P450 Family 4 , Ethnicity , Humans , International Normalized Ratio , Middle Aged , Mixed Function Oxygenases/genetics , Publication Bias , Sex Factors , Vitamin K Epoxide Reductases
14.
Clin Pharmacol Ther ; 91(4): 660-5, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22378156

ABSTRACT

The cytochrome P450 (CYP) 2C9 R150H (*8) allele occurs commonly in African Americans and is associated with lower warfarin dose requirements. We conducted a pharmacokinetic study to examine whether the CYP2C9*8 allele impacts warfarin clearance in African-American patients. We also conducted an in vitro kinetic study of S-warfarin 7-hydroxylation using complementary DNA (cDNA)-expressed CYP2C9 enzymes. We observed a 30% reduction in the unbound oral clearance of S-warfarin and a 25% lower R- to S-warfarin plasma concentration ratio in patients with the CYP2C9*8 allele (n = 12) as compared to CYP2C9*1 homozygotes (n = 26). Consistent with these findings, the in vitro intrinsic clearance of S-warfarin was 30% lower with the cDNA-expressed R150H protein as compared to the wild-type protein. These data show that the R150H variant protein expressed by the CYP2C9*8 allele is associated with lower S-warfarin clearance. This finding provides clinical and experimental evidence to explain the lower warfarin dose requirements in patients with the CYP2C9*8 allele.


Subject(s)
Aryl Hydrocarbon Hydroxylases/genetics , Polymorphism, Genetic/genetics , Warfarin/pharmacokinetics , Adult , Black or African American/genetics , Aged , Cytochrome P-450 CYP2C9 , Female , Genetic Variation/genetics , Hep G2 Cells , Humans , Male , Metabolic Clearance Rate/genetics , Middle Aged
15.
Clin Pharmacol Ther ; 90(4): 519-31, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21918509

ABSTRACT

The past decade has seen substantial advances in cardiovascular pharmacogenomics. Genetic determinants of response to clopidogrel and warfarin have been defined, resulting in changes to the product labels for these drugs that suggest the use of genetic information as a guide for therapy. Genetic tests are available, as are guidelines for incorporation of genetic information into patient-care decisions. These guidelines and the literature supporting them are reviewed herein. Significant advances have also been made in the pharmacogenomics of statin-induced myopathy and the response to ß-blockers in heart failure, although the clinical applications of these findings are less clear. Other areas hold promise, including the pharmacogenomics of antihypertensive drugs, aspirin, and drug-induced long-QT syndrome (diLQTS). The potential value of pharmacogenomics in the discovery and development of new drugs is also described. In summary, pharmacogenomics has current applications in the management of cardiovascular disease, with clinically relevant data continuing to mount.


Subject(s)
Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control , Global Health , Health Behavior , Humans
16.
Clin Pharmacol Ther ; 89(3): 408-15, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21270790

ABSTRACT

It is well recognized that the genetic variants VKORC1-1639, CYP2C9*2, and CYP2C9*3 contribute to warfarin dose response. This has led to warfarin dosing algorithms that include these polymorphisms and explains between 47% and 56% of variability in dose in Caucasians. However, these polymorphisms explain significantly less of the variance in dose among African Americans. In order to identify novel variations that affect warfarin dose in African Americans, we used a targeted resequencing strategy that examined evolutionarily conserved sequences and regions of putative transcriptional binding. Through ethnicity-specific warfarin dose model building in 330 African Americans, we identified two novel genetic associations with higher warfarin dose, namely, VKORC1-8191 (rs61162043, P = 0.0041) and 18786 in CYP2C9 (rs7089580, P = 0.035). These novel finds are independent of the previous associations with these genes. Our regression model, encompassing both genetic and clinical variables, explained 40% of the variability in warfarin dose in African-American subjects, significantly more than any model thus far.


Subject(s)
Anticoagulants/administration & dosage , Aryl Hydrocarbon Hydroxylases/genetics , Black or African American/genetics , Mixed Function Oxygenases/genetics , Warfarin/administration & dosage , Algorithms , Anticoagulants/pharmacokinetics , Base Sequence , Cohort Studies , Cytochrome P-450 CYP2C9 , Dose-Response Relationship, Drug , Female , Genetic Variation , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide , Regression Analysis , Vitamin K Epoxide Reductases , Warfarin/pharmacokinetics
17.
Clin Pharmacol Ther ; 87(4): 445-51, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20200517

ABSTRACT

Warfarin demonstrates a wide interindividual variability in response that is mediated partly by variants in cytochrome P450 2C9 (CYP2C9) and vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1). It is not known whether variants in calumenin (CALU) (vitamin K reductase regulator) have an influence on warfarin dose requirements. We resequenced CALU regions in a discovery cohort of dose outliers: patients with high (>90th percentile, n = 55) or low (<10th percentile, n = 53) warfarin dose requirements (after accounting for known genetic and nongenetic variables). One CALU variant, rs339097, was associated with high doses (P = 0.01). We validated this variant as a predictor of higher warfarin doses in two replication cohorts: (i) 496 patients of mixed ethnicity and (ii) 194 African-American patients. The G allele of rs339097 (the allele frequency was 0.14 in African Americans and 0.002 in Caucasians) was associated with the requirement for a 14.5% (SD +/- 7%) higher therapeutic dose (P = 0.03) in the first replication cohort and a higher-than-predicted dose in the second replication cohort (allele frequency 0.14, one-sided P = 0.03). CALU rs339097 A>G is associated with higher warfarin dose requirements, independent of known genetic and nongenetic predictors of warfarin dose in African Americans.


Subject(s)
Anticoagulants/administration & dosage , Black or African American/genetics , Calcium-Binding Proteins/genetics , Mixed Function Oxygenases/metabolism , Warfarin/administration & dosage , Adult , Aged , Alleles , Cohort Studies , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Polymorphism, Single Nucleotide , Vitamin K Epoxide Reductases , White People/genetics
18.
Clin Pharmacol Ther ; 87(4): 459-64, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20072124

ABSTRACT

The objective of this study was to determine whether, in African-American patients, additional vitamin K oxidoreductase complex subunit 1 (VKORC1), cytochrome P450 2C9 (CYP2C9), CYP4F2, or apolipoprotein E (APOE) polymorphisms contribute to variability in the warfarin maintenance dose beyond what is attributable to the CYP2C9*2 and *3 alleles and the VKORC1 -1639G>A genotype. In a cohort of 226 African-American patients, weekly warfarin dose requirements were lower in those with the CYP2C9*8 allele (34 (30-47) mg; P = 0.023) and the CYP2C9 *2, *3, *5, *6, or *11 allele (33(28-40 mg); P < 0.001) as compared with those with the CYP2C9*1/*1 genotype (43 (35-56) mg). The combination of CYP2C9 alleles, VKORC1 -1639G>A genotype, and clinical variables explained 36% of the interpatient variability in warfarin dose requirements. By comparison, a model without the CYP2C9*5, *6, *8, and *11 alleles explained 30% of the variability in dose. No other VKORC1, CYP4F2, or APOE polymorphism contributed to the variance. The inclusion of additional CYP2C9 variants may improve the predictive ability of warfarin dosing algorithms for African Americans.


Subject(s)
Anticoagulants/administration & dosage , Apolipoproteins E/genetics , Aryl Hydrocarbon Hydroxylases/genetics , Mixed Function Oxygenases/genetics , Warfarin/administration & dosage , Adult , Black or African American/genetics , Aged , Algorithms , Alleles , Cytochrome P-450 CYP2C9 , Dose-Response Relationship, Drug , Female , Genotype , Humans , Male , Middle Aged , Polymorphism, Genetic , Vitamin K Epoxide Reductases
19.
Int J Clin Pharmacol Ther ; 46(7): 365-74, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18793590

ABSTRACT

OBJECTIVES: To compare cytochrome P450 activity in people with and without cancer and examine the relationship between CYP2C9 activity and serum cytokine levels. PATIENTS AND METHODS: 10 subjects with cancer who were currently receiving treatment and 10 additional subjects without cancer who were matched to the subjects with cancer based on gender and race were enrolled into the study. Serial blood samples were drawn to measure tolbutamide in the plasma before and after oral tolbutamide 500 mg. Total urine excreted was collected from 0 to 12 h following the dose. Tolbutamide and its metabolites were measured in plasma and urine by HPLC. CYP2C9 genotype was determined by PCR and pyrosequencing and cytokine values were determined by ELISA. RESULTS: The mean apparent oral clearance (cancer, 19.5 +/- 10.5 vs. non-cancer, 15.8 +/- 5.0 ml/min) and the mean urinary metabolic ratio from 0 to 12 h were similar (838 +/- 693 vs. 775 +/- 390). Neither age nor genotype statistically affected the outcomes. Mean interleukin-6 (7.2 +/- 9.4 vs. 1.5 +/- 1.3 pg/ml) and tissue necrosis factor-a (26.2 +/- 71.2 vs. 1.5 +/- 1.3 pg/ml) were 5- to 7-fold higher, respectively, in subjects with cancer. No statistically significant correlation between cytokine values and oral clearance or urinary metabolic ratio was found. CONCLUSIONS: CYP2C9 activity as measured by apparent oral clearance and urinary metabolic ratio following oral tolbutamide appear similar in people with and without cancer. Serum cytokine values appear higher in patients with cancer, although the differences did not reach statistical significance.


Subject(s)
Aryl Hydrocarbon Hydroxylases/metabolism , Hypoglycemic Agents/pharmacokinetics , Neoplasms/metabolism , Tolbutamide/pharmacokinetics , Administration, Oral , Adult , Age Factors , Aged , Case-Control Studies , Chromatography, High Pressure Liquid , Cytochrome P-450 CYP2C9 , Female , Genotype , Humans , Interleukin-6/metabolism , Male , Middle Aged , Prospective Studies , Tumor Necrosis Factor-alpha/metabolism
20.
Pharmacogenomics J ; 8(6): 408-15, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18253135

ABSTRACT

Our objective was to determine if beta(1)-adrenergic receptor (beta(1)-AR) and beta(2)-AR gene polymorphisms influence heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) response to dobutamine during dobutamine stress echocardiography (DSE). Patients (n=163) undergoing clinically indicated DSE were enrolled. Dobutamine doses were titrated from 5 to 40 microg kg(-1) min(-1) at 3 min intervals and HR, SBP and DBP were measured. Genotypes were determined for beta(1)-AR Ser49Gly, beta(1)-AR Arg389Gly, beta(2)-AR Arg16Gly and beta(2)-AR Gln27Glu polymorphisms by polymerase chain reaction-restriction fragment length polymorphism analysis, pyrosequencing and single primer extension methods. beta(2)-AR Glu27 homozygotes had a greater HR response at the highest dobutamine dose than Gln27 carriers (P=0.002). Beta(2)-AR Gly16 homozygotes had a lower HR response during 5-30 microg kg(-1) min(-1) of the dobutamine infusion protocol compared to Arg16 carriers (P=0.03). Differences in SBP by beta(2)-AR codon 16 genotype and DBP by beta(1)-AR codon 389 genotype were found at baseline and were maintained throughout DSE (P=0.06 and 0.02, respectively). However, the magnitude of SBP and DBP response to dobutamine did not differ significantly by beta(2)-AR codon 16 or beta(1)-AR codon 389 genotypes, respectively. These data suggest that the four selected beta(1)- and beta(2)-AR polymorphisms do not substantially influence the magnitude of hemodynamic response to dobutamine during DSE.


Subject(s)
Blood Pressure/drug effects , Dobutamine/administration & dosage , Echocardiography/methods , Heart Rate/drug effects , Polymorphism, Genetic , Receptors, Adrenergic, beta/genetics , Aged , Cohort Studies , Dobutamine/pharmacology , Female , Genotype , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL